Overview

Safety and Efficacy of 2 Treatment Regimens of Aztreonam for Inhalation Solution in Children With Cystic Fibrosis and New Onset Pseudomonas Aeruginosa Infection

Status:
Completed

Trial end date:
2021-09-23

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the safety and efficacy of a 14-day course versus a 28-day course of aztreonam for inhalation solution (AZLI) in participants with new onset Pseudomonas aeruginosa respiratory tract infection.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Aztreonam